Modern approaches to the management of homozygous familial hypercholesterolemia in the Middle East and North Africa
Abdullah Al‐Ashwal(King Faisal Specialist Hospital & Research Centre), Dirk Blom(University of Cape Town), Zuhier Awan(King Abdulaziz University), Tawfeg Ben‐Omran(Qatar Airways (Qatar)), Ahmed Al-Sarraf(Ministry of Health), Afaf Alsagheir(King Faisal Specialist Hospital & Research Centre), Mutaz Al-Khnifsawi(European Society of Hypertension), Mohammed Al Dubayee(King Saud bin Abdulaziz University for Health Sciences), Naji Kholaif(Alfaisal University), Faouzi Maatouk(Hospital Fatuma Bourguiba Monastir), Manal Alshareef(National Guard Health Affairs), Abdelhadi Habeb(Prince Mohammed bin Abdulaziz Hospital), Angham Almutair(National Guard Health Affairs), Saif Al-Yaarubi(Oman Medical College)
Cited by 6
Related Papers
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
|The Lancet|2012|739
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
|New England Journal of Medicine|2019|663